secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001819790-24-000062
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q1 2024: XDEMVY sales $24.7M (+89% QoQ), net loss $35.7M, cash $298.5M
-----------------------------------------------------------------------------

- Q1 net product sales of XDEMVY $24.7M, up 89% from Q4 2023; ~26,000 bottles delivered (65% increase).
- Net loss of $35.7M ($1.01 loss per share) vs $23.4M loss in Q1 2023.
- SG&A expenses surged to $51.6M from $15.1M due to commercial launch costs.
- Cash and marketable securities $298.5M as of Mar 31; secured $200M credit facility in Apr 2024 (drew $75M).
- Secured commercial payer contracts covering ~18M lives on preferred status; broad coverage expected by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000062/0001819790-24-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000062/tars-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001819790-24-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer